Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs ThredUp Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while ThredUp Inc trades at $2.19 (market cap $303.38M). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 29.2× ThredUp Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and ThredUp Inc for 29 Days on average.
| KYMR | TDUP | |
|---|---|---|
Market Cap | $8.87B | $303.38M |
Volume | 779,107 | 1,426,025 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $9.38 |
52-Week Low | $55.80 | $2.12 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $8.26B | $301.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ThredUp (TDUP) trades at $2.2, down 11.29% in the last session, with a bullish technical signal from moving averages but mixed oscillators. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed EPS estimates and cut full-year revenue guidance. Cash flow from operations improved to $10.65 million in 2025, though net income remains negative. Analyst consensus is 57% buy, with no sell ratings, but recent news highlights promotional headwinds and a securities investigation.
The outlook is cautious; revenue growth and high gross margins are positives, but persistent losses, weak guidance, and legal risks pose challenges. The stock's low price-to-sales ratio of 0.88 may attract value investors, yet profitability concerns and negative ROE of -36.76% underscore significant execution risk. Investors should weigh strong analyst support against fundamental weaknesses and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
